The U.S. Food and Drug Administration (FDA) approved Prestalia, a fixed-dose combination of perindopril arginine and amlodipine, on Jan. 21. The drug provides treatment to patients with hypertension who are otherwise unable to control their blood pressure (BP) on monotherapy. According to the FDA, the drug is also approved for initial therapy in patients who require treatment with multiple drugs. In the clinical trial, the combination of perindopril arginine and amlodipine resulted in greater improvements in diastolic and systolic BP than either on its own.

Keywords: Amlodipine, Arginine, Blood Pressure, Blood Pressure Determination, Diastole, Hypertension, Perindopril, Pharmaceutical Preparations, United States, United States Food and Drug Administration

< Back to Listings